Clinical trials

Filters
Clear filters
22 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionNCT02065336Arrowhead PharmaceuticalsPhase 2Terminated2017-01Actual
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionNCT02604199Arrowhead PharmaceuticalsPhase 2Terminated2017-01Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionNCT02738008Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)NCT03945292Arrowhead PharmaceuticalsPhase 2Completed2021-11-08Actual
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)NCT03946449Arrowhead PharmaceuticalsPhase 2Completed2022-04-28Actual
Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaNCT04720534Arrowhead PharmaceuticalsPhase 2Completed2023-03-09Actual
Study of ARO-ANG3 in Adults With Mixed DyslipidemiaNCT04832971Arrowhead PharmaceuticalsPhase 2Completed2022-08-30Actual
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaNCT04998201Arrowhead PharmaceuticalsPhase 2Completed2023-02-10Actual
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)NCT05089084Arrowhead PharmaceuticalsPhase 3Completed2024-04-29Actual
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)NCT05217667Arrowhead PharmaceuticalsPhase 2Terminated2023-05-02Actual
Study of ARO-APOC3 in Adults With DyslipidemiaNCT05413135Arrowhead PharmaceuticalsPhase 2Completed2025-09-22Actual
Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003Arrowhead PharmaceuticalsPhase 3Completed2026-06-12Actual
Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016Arrowhead PharmaceuticalsPhase 3Completed2026-06-17Actual
Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133Arrowhead PharmaceuticalsPhase 3Completed2026-06-01Actual
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaNCT06822790Arrowhead PharmaceuticalsPhase 3Active not recruiting2028-07Estimated
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisNCT06880770Arrowhead PharmaceuticalsPhase 3Recruiting2029-03Estimated
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)NCT07037771Arrowhead PharmaceuticalsPhase 3Active not recruiting2027-08-20Estimated
Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaNCT07241546Arrowhead PharmaceuticalsPhase 2Recruiting2027-12Estimated
Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaNCT07473843Arrowhead PharmaceuticalsPhase 3Recruiting2028-07Estimated

Primary completion marks the end of data collection for the main study measures, not a results publication date.